IOVA
Iovance Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.79
+1.03%Margins
Gross margin
116.3%
EBITDA margin
-80.9%
EBIT margin
-92.7%
Net margin
-89.1%
FCF margin
-91.2%
-39.3%
Return on equity
-31.6%
Return on assets
-38.5%
Return on invested capital
0.35x
Asset turnover
-$264.2M
Cash from operations
$0.66
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026